| Literature DB >> 35369629 |
Justyna Cwajda-Białasik1,2, Paulina Mościcka1,2, Maria T Szewczyk1,2.
Abstract
Introduction: The development of the field related to the treatment of wounds has resulted in the appearance of new antimicrobial active ingredients. Aim: To analyse, evaluate and systematize the available scientific evidence of the effectiveness and safety of antiseptic preparations intended for the treatment of chronic wounds. Material and methods: We conducted a literature review using the advanced search engine in the PubMed database. We used a combination of two English keywords, i.e.: "antiseptic" and "chronic wound". We have selected only clinical, randomized controlled trials.Entities:
Keywords: antiseptic; chronic wound; medical device; pharmacological drug
Year: 2022 PMID: 35369629 PMCID: PMC8953877 DOI: 10.5114/ada.2022.113807
Source DB: PubMed Journal: Postepy Dermatol Alergol ISSN: 1642-395X Impact factor: 1.837
Criteria differentiating antiseptics (pharmacological drugs, drugs) and medical devices (other preparations containing substances with antimicrobial activity, not being a drug, but in accordance with their intended use for cleaning, irrigation and wound care)
| Category | Pharmacological drug, PD | Medical device, MD |
|---|---|---|
| Mechanism of action | Pharmacological, biochemical, metabolic and/or immunological mechanism leading to the inhibition, prevention or killing of bacteria (biocidal effect) | The primary mechanism of action is physical cleansing (i.e. washing/lavaseptic, absorption, moisture regulation or irreversible physicochemical binding of microorganisms) – the antimicrobial effect is only due to the addition of preservatives |
| Composition | Full description of the composition including the individual components of the preparation and their quantity (concentration, proportions, etc.), indications and microbiological effectiveness | Composition taking into account the main components of the preparation (quantitative composition may be given but is not required) |
| Registration category* | Pharmacological drug – is an ingredient or mixture of ingredients with properties for the prevention or treatment of disease in humans and animals; | Medical device – is a tool, instrument, apparatus, equipment, material or other article used alone or in combination, including software necessary for the proper application of the product, intended by the manufacturer for use in humans for the diagnosis, prevention, monitoring or alleviation of the course of disease. |
| Efficiency and safety | Confirmed both in | Not always confirmed by |
| Indications | Prevention and treatment of wound infections | Wound cleansing, supporting the prevention and treatment of wound infections |
| An example of active ingredients | 10% PVP-I, polyvinylpyrrolidone-iodine | In irrigation fluids (lavaseptics): |
*based on: Definition of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Pharmaceutical Law Act of 6 September 2001 (Journal of Laws of 2020, item 944), Act on medical devices of 20 May 2010 (Journal of Laws of 2020, item 186), Regulation of the Minister of Health on the determination of groups of medicinal products and the requirements for the results of tests of these products of 11 August 2005 (Journal of Laws of 24 August 2005), Kramer A, et al. Consensus on wound antisepsis: update 2018. Skin Pharmacol Physiol 2018; 31: 28-58. Bartoszewicz M, et al. Principles of local and general management in chronic wounds/ulcers covered by the infection process. Infection Forum 2019; 10: 1-30.
Criteria for qualifying the article for analysis
| Study type | Randomized, single or multicentre, with or without control, or observational with a control group |
|---|---|
| Study group | Adult patients with chronic wounds, regardless of aetiology (excluding neoplastic and unclassified wounds, as well as wounds and lesions involving mucous membranes) |
| Interventions | A preparation containing an antimicrobial substance, regardless of the form (liquid, gel, powder, impregnation), intended for the care and/or treatment of chronic wounds |
| Control group | Standard care or other alternative antimicrobial treatment of wounds at risk of infection or infected |
| Measure of the effectiveness of the preparation | Progress of the healing process and/or demonstrated microbiological effect, side effects/complications, others |
Summary of data from the analysis of clinical trials assessing the efficacy and tolerability of antimicrobial preparations in the treatment of chronic wounds
| Author, year | Sample size, | Type of wound | Comparison | Results and conclusions |
|---|---|---|---|---|
| Malone (2019) [ | 9/9 | DFU | Cadexomer iodine 0.9%; ointment (2 vs. 6 weeks) | No differences in the results due to the duration of therapy. Total microbial load and community composition decrease (assessed by real-time qPCR method and SEM) – after 2 weeks and 6 weeks was comparable |
| Raju (2019) [ | 41/43/40 | VLU | 0.9% cadexomer iodine ointment or powder vs. standard care (12 weeks) | Significantly better results achieved when standard care was combined with an antiseptic than with no care |
| Assadian (2018) [ | 11[13]/20[23]/ 22[27]/14[14]/ | Chronic wounds of various aetiology (VLU, AU, DFU, PI, others) | The antibacterial effect of different irrigation solutions during a 20-minute wet-to-moist treatment of chronic wounds has been studied | All irrigation solutions excluding 0.9% NaCl and H2O + lithium-magnesium-sodium-silicate, Sal Maris, nascending O2 (Biosept), significantly reduce the planktonic bacterial burden on wounds. The highest reduction was noted at: cocamidopropyl betaine, zinc, iron, polyhexamethylene biguanide (Nawalution), then sea salt 3% and 0.2% sodium hypochlorite (Actimaris Forte 3%) and 10% povidone-iodine (PVP-I) solution with 10% free iodine (the most statistically significant decrease in the number of bacteria), hypochlorite (ClO−) and hypochlorous acid (HCIO) |
| Kim (2018) [ | 22/21 | Chronic wounds of various aetiology | Biofilm-disrupting wound gel vs. a triple-antibiotic ointment (12 weeks) | Greater progress in the healing process in the group treated with the gel (wound healing: 71% vs. 24%). Microbiological analysis showed no correlation between the presence of bacteria in the wound, or the number of identified species of microorganisms and the effect on the healing process |
| Madhusudhan (2016) [ | 16/16 | Chronic wounds infected with | 1% acetic acid vs. 0.9% NaCl (24 weeks) | The duration of treatment required to eliminate the Pseudomonas from the wounds in the acetic acid group was on an average 7 days less than that required by the saline group |
| Wolcott (2015) [ | 15/15/15 | Chronic wounds of various aetiology (VLU, AU, DFU, PI others) | Standard care/biofilm-disrupting wound gel/gel + standard care (12 weeks) | Significantly higher percentage of the healed area in the group using the gel or gel in combination with standard care compared to the standard care alone without the gel (53% vs. 80% vs. 93%). In this study, the biofilm structure in wounds and the actual effect of the gel on the biofilm were not identified |
| Hämmerle & Strohal (2014) [ | 15[15]/14[17]/15[17]* | VLU | OCT gel + specialist dressing/OCT gel + gauze/specialist dressing (6 weeks) | Significantly better effectiveness (% healed area) and tolerance of OCT gel and OCT gel in combination with a dressing than the dressings alone. No differences between the groups in the incidence of infections at the end of therapy |
| Krasowski | 40/40 | VLU | “Sandwich” (multilayered) dressing consisted of layers having different forms of OCT (gel, solution and antiseptic) vs. silver dressing, absorbent dressing and Ringer’s solution (8 weeks) | Significantly better healing dynamics (1.58 vs. 0.23 cm2/week), higher percentage of the wound area healed: (58% vs. 14%), degree of microbiological eradication (21.7% vs. 3.1%) after 4 weeks and after 8 weeks (69.6% vs. 43.8%) and 1.37 times greater decrease in pain intensity in the study group |
| Ulrich (2015) [ | 10[10]/10[10]* | Ulceration of vascular aetiology | OCT antiseptic vs. APP (2 weeks) | Better effectiveness of OCT than APP – higher microbiological reduction immediately after treatment (64 vs. 47%) and influence on bacterial density after 2 weeks of therapy (–35% vs. + 12%). Tolerance of both methods – comparable |
| Klebes (2015) [ | 34 (3 groups) | E.g. ulcers of various aetiologies | TTP or OCT or TTP + OCT | Bacterial colonization (assessed before and after debridement) was most significantly reduced in the TTP + OCT combination group compared to monotherapy |
| Woo (2019) [ | 34 (2 groups) | Critically colonized wounds | Antimicrobial dressing with silver alginate powder vs. normal saline solution gauze dressing group (4 weeks) | A significantly better effect (reduction in bacterial load and reduction in the wound surface) was achieved in the group using the silver preparation |
| Vanscheidt (2012) [ | 60/66 | VLU | OCT antiseptic vs. Ringer solution (12 weeks) | No statistically significant advantage of the OCT preparation in the parameters of the healing process (time to wound closure, number of healings, healing dynamics were comparable). There were fewer complications in the group using OCT as compared to the Ringer’s solution (16.7 vs. 28.8%) |
| Sibbald (2012) [ | 23/22 | Lower limb ulceration | PHMB foam dressing vs. foam dressing (4 weeks) | The use of PHMB foam dressing was a significant predictor of reduced wound superficial bacterial burden. PHMB foam dressing successfully reduced chronic wound pain and bacterial burden |
| Arenbergerova (2012) [ | 84/39/39 | VLU | Polyurethane fabric made of nanofibers (NT, nanofibre textile) with an admixture of tetraphenylporphyrin – TPP (photosensitizer) subjected to photo exposure vs. NT without TPP and NT with TPP kept in the dark | High antibacterial effectiveness of light-activated, antibacterial nanofibers with TPP admixture (significant inhibition of bacterial growth, reduction in the wound area by 35% and pain reduction by 71%). Bacterial photoinactivation, dependent on the production of highly reactive, short-lived singlet oxygen O2 (1Dg), resulted in a relatively superficial antibacterial effect and did not interfere with the ulcer healing process |
| Romanelli (2010) [ | 20/20 | VLU | PHMB solution vs. 0.9% NaCl (4 weeks) | In the group treated with PHMB, a favourable decrease in wound pH (from 8.9 to 7.0) was achieved, in the control group the pH was stable at 8.5. In the study group, better tolerance, pain reduction and odour absorption |
| Woo (2010) [ | 20/22 | Infected chronic wounds of various aetiology (VLU, AU, DFU, PI, others) | Silver alginate wound dressing vs. alginate dressing (2 weeks) | The regression of local signs of infection, local tolerance, acceptability and usefulness were similar for the two dressings. However, silver alginate wound dressing improved the bacteriological status of the wounds |
| Miller (2009) [ | 133/133 | VLU, MU | Cadexomer iodine vs. nanocrystalline silver (12 weeks) | The performance of each of the two antimicrobials was comparable in terms of the overall healing rate and the number of wounds healed. However, use of silver compounds was associated with a quicker healing rate during the first 2 weeks of treatment and in wounds that were larger, older, and had more exudate |
| Kotz (2009) [ | 126 | Chronic wounds with high exudate and risk of infection | 3 types of Ag foam dressing (adhesive, non-adhesive and sacral) (Me = 21) | Non-comparative assessment of silver foam dressings – all were well tolerated (88.3% of wounds). Clinical symptoms of infection were reduced (from 68.1% to 31%) or cured (clinical infection in the final evaluation only in 8.5% of patients) |
| Calow (2008) [ | 251 | Chronic wounds of various aetiology (VLU, AU, DFU, PI, others) | OCT/PE (2 weeks) without any control group | The presence of contact dermatitis after OCT/PE was assessed. Local symptoms of contact dermatitis in |
| Hauser (2006) [ | 83/84 | Skin graft collection sites and locations (chronic wounds, burns) | Povidone iodine liposome hydrogel (PVP-I-L) 3% + soft paraffin dressing vs. soft paraffin dressing alone (until the wound is healed) | A significantly better microbicidal activity and tissue tolerability of the PVP-I-L hydrogel compared to conventional PVP-I formulations was shown. PVP-I-L hydrogel combines microbicidal and wound healing activities resulting in enhanced epithelization. Rejections of transplants: 8 (9.9%) vs. 20 (26.7%) |
| Münter (2006) [ | 326/293 | Chronic wounds of various aetiology (VLU, AU, DFU, PI, others) | Sustained silver-releasing foam dressing vs. best local practice (BLP) (4 weeks) | The foam dressing with a prolonged release mechanism of silver ions (up to 7 days) exceeded BPL and all other dressing categories in all aspects assessed (reduction in the wound surface, reduction in exudate, fibrin and necrosis; improved quality of life and longer wear time) |
| Daróczy (2006) [ | 21/21/21 | VLU (patients presenting ulcerated stasis dermatitis due to deep venous reflux) | PVP-I with or without compression therapy vs. systemic antibiotic with compression therapy (12 weeks) | Number of healings in individual groups: 82%, 62%, 85% |
| Lansdown | 7 | Chronic wounds of various aetiology | Silver dressings (Acticoat-7, Actisorb Silver, Contreet Foam, Aquacel Ag and Flamazine) | Silver dressings were found to be safe for use in chronic wound therapy |
| Karlsmark (2003) [ | 25 | VLU | Sustained silver-releasing dressing (4 weeks) without any control group | The tested dressing turned out to be safe, beneficial for the healing process and ensuring control of exudate: reduction in the ulcer area by 56%, increase in granulation tissue, reduction in unpleasant odour (after 1 week), average wear time 3.1 days |
| Nagl (2003) [ | 20/20 | Leg ulcers | G1: N-chlorotaurine (NCT) vs. chloramine T (CAT) (median of 7 days (range: 3–14)) | Therapeutic effectiveness of treatment (decrease in bacterial load) comparable. The intensity of pain in both groups increased after the application of the preparation, more so in the case of CAT (more often pain preventing the continuation of therapy). Less toxicity, greater granulation growth, and re-epithelization in NCT |
| Piérard-Franchimont (1997) [ | 15/15 | VLU | 10% PVP-J (Betadine) + hydrocolloid dressing vs. hydrocolloid dressing alone (8 weeks) | Significantly better healing results were achieved in the study group (4 and 8 weeks). Greater bacterial load and inflammatory infiltrate in the group using the dressing alone |
| Ormiston (1985) [ | 30/30 | VLU | Cadexomer iodine 0.9% (powder) vs. dressing with gentian violet and polymyxin and bacitracin ointment (12 weeks) | Comparison of the effectiveness of two preparations in cross-over therapy – 12-week change of methods between groups. Greater dynamics of healing, but also more side effects (stinging, itching, eczema, rash) in the group using iodine cadexomer. Improvement in granulation, oedema, exudate, pus and erythema comparable in both groups |
| Kucan (1981) [ | 15/11/14 | PI | Silver sulfadiazine, 1% (cream) vs. PVP-J vs. 0.9% NaCl (3 weeks) | All the preparations used resulted in the reduction in the bacterial count below the critical level of 105/g of tissue (after 3 weeks: 100%, 78.6%, 63.6%), however, silver sulfadiazine in a much shorter time |